Induction of apoptosis by ubenimex (Bestatin®) in human non-small-cell lung cancer cell lines

Biomedicine and Pharmacotherapy

Volumn 50, Issue 6-7, 1996, Pages 283-289

  Ezawa, K ^a   Minato, K ^a   Dobashi, K ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Non small cell lung cancer; Ubenimex Bestatin

Indexed keywords

BESTATIN; DNA FRAGMENT; MARKER; MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL;

EID: 0029781804     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/0753-3322(96)84827-X     Document Type: Article

References (20)

1. 1 Umezawa H, Aoyagi T, Suda H, Hamada M, Takeuchi T. Bestatin®, an inhibitor of amino peptidase B, produced by actinomycetes. J Antibiotics 1976;29:97
2. 2 Talmadge JE, Koyama M, Matsuda A, Long C, Abe F. Immunotherapeutic properties of Bestatin®: mechanism of activity. Recent Results of Bestatin®, Tokyo, 1986:8
3. 3 Talmadge JE, Pelus LM, Black PL, Abe F. Hematopoietic and therapeutic properties of Bestatin® in normal and myelosuppressed mice. Biomed Pharmacother 1991;45:61
4. 4 Talmadge JE, Lenz BF, Pennington R et al. Immunomodulatory and therapeutic properties of Bestatin® in mice. Cancer Res 1986;46:4505
5. 5 Schorlemmer HU, Bosslet K, Sedlacek HH. Ability of the immunomodulating dipeptide Bestatin® to activate cytotoxic mononuclear phagocytes. Cancer Res 1983;43:4148
6. 6 Schorlemmer HU, Bosslet K, Dickneite G, Luben G, Sedlacek HH. Studies on the mechanisms of action of the immunomodulator Bestatin® in various screening test systems. Behring Inst Mitt 1984;74:157
7. 7 Bruley-Rosset M, Payelle B, Rappaport H. Acceleration of age-associated immune decline and mortality by early repeated administration of Bestatin® to C57BL/6 mice. J Biol Resp Modif 1986;5:176
8. 8 Fukuoka M, Takada M, Negoro S et al. Randomized, controlled trial of combination therapy with ubenimex in inoperable lung cancer. Biotherapy 1989;3(6):1504
9. 9 Yokota S, Nishikawa H, Furuse K et al. Double-blind study of ubenimex (NK421: Bestatin®) on squamous cell lung cancer. Proceeding of ASCO Vol 12 March 1993
10. 10 Twentyman PR, Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987;56:279
11. Y antigen expression is correlated with apoptosis (programmed cell death). Glycobiology 1993;3:381
12. 12 Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972;26:239
13. 13 Wyllie AH. Cell death: a new classification separating apotosis from necrosis. In: Bowen ID, Lockshin RA, eds. Cell Death in Biology and Pathology. London: Chapman & Hall, 1981:9
14. 14 Lloyd KO, Kabat EA, Layug EJ, Gruezo F. Immunochemical studies on blood groups: XXXIV. Structures of some oligosaccharides produced by alkaline degradation of blood group A, B, and H substances. Biochemistry 1966; 5:1489
15. 2FucnLc6). J Biol Chem 1986;261:11247
16. 16 Abe K, McKibbin JM, Hakomori S. The monoclonal antibody directed to difucosylated type 2 chain (Fuc α1-2Gal β1-4 [FucÉø1-3] G1cNAc;Y determinant). J Biol Chem 1983;258:11793
17. 17 Brown A, Feizi T, Gooi HC, Embleton MJ, Picard JK, Baldwin RW. A monoclonal antibody against human colonic adenoma recognizes difucosylated type 2 blood group chains. Biosci Rep 1983;3:163
18. 18 Lloyd KO, Larson G, Stromberg N, Thurin J, Karlsson KA. Mouse monoclonal antibody F-3 recognizes the difucosyl Type 2 blood group structure. Immunogenetics 1983; 17:537
19. 19 Koyama M, Hashimoto M, Asakawa N, Ishibashi M, Miyazaki H. Simultaneous determination of Bestatin® and p-hydroxybestatin, a major metabolite, in human serum by gas chromatography mass spectrometry. Biomedical Mass Spectrometry 1980;7:372
20. 20 Tsunogake S, Takano N, Enokihara H, Furusawa S, Shishido H. Differential effects of ubenimex on growth of normal human haematopoietic progenitors and leukemic cells in vitro. Int J Immunotherapy 1991;7:63